Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the
EMPA‐REG OUTCOME
trial
2020 ◽
Vol 22
(12)
◽
pp. 2335-2347
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):